From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .
Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .
ASXL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ASXL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
GNB1 Human Pre-designed siRNA Set A contains three designed siRNAs for GNB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TET2 Human Pre-designed siRNA Set A contains three designed siRNAs for TET2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters . Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) . Laniquidar has limited oral bioavailability .
BMS-986397 is a cereblon-based CK1α (casein kinase 1α) molecular glue degrader that can cause rapid apoptosis and cell cycle arrest in TP53 wild-type AML (acute myeloid leukemia) cells. BMS-986397 can be used for the study of AML and HR-MDS (High-Risk Myelodysplastic Syndrome) .
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation.
Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
YWHAE Human Pre-designed siRNA Set A contains three designed siRNAs for YWHAE gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pseudouridine- 13C, 15N2 is the 13C- and 15N-labeled Pseudouridine (HY-113061). Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
SF3B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SF3B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAFAH1B1 Human Pre-designed siRNA Set A contains three designed siRNAs for PAFAH1B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
Pipobroman (Standard) is the analytical standard of Pipobroman. This product is intended for research and analytical applications. Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .
Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation.
Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
The LSM3 protein plays a crucial role in pre-mRNA splicing as a component of the U4/U6-U5 tri-snRNP complex involved in spliceosome assembly and as part of the precatalytic spliceosome (spliceosome B complex). The heptameric LSM2-8 complex (including LSM3) specifically binds to the 3'-end U strand of U6 snRNA. LSM3 Protein, Human (His) is the recombinant human-derived LSM3 protein, expressed by E. coli , with N-His labeled tag.
14-3-3 epsilon proteins are adapter proteins in various signaling pathways that bind to phosphoserine or phosphothreonine motifs to regulate chaperone activity.It positively regulates HSF1 nuclear export to the cytoplasm, forming homo- and heterodimers with YWHAZ.14-3-3 epsilon Protein, Mouse (His) is the recombinant mouse-derived 14-3-3 epsilon protein, expressed by E.coli , with N-6*His labeled tag.
Pseudouridine- 13C, 15N2 is the 13C- and 15N-labeled Pseudouridine (HY-113061). Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
TET2 Antibody (YA4336) is a mouse-derived and non-conjugated IgG1 antibody, targeting to TET2. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human.
LIS1 Antibody (YA3173) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3173), targeting LIS1, with a predicted molecular weight of 47 kDa (observed band size: 47 kDa). LIS1 Antibody (YA3173) can be used for WB, IP experiment in hamster, rat background.
Y14 Antibody (YA2439) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2439), targeting Y14, with a predicted molecular weight of 20 kDa (observed band size: 20 kDa). Y14 Antibody (YA2439) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation.
Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .
ASXL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ASXL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
GNB1 Human Pre-designed siRNA Set A contains three designed siRNAs for GNB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TET2 Human Pre-designed siRNA Set A contains three designed siRNAs for TET2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
YWHAE Human Pre-designed siRNA Set A contains three designed siRNAs for YWHAE gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SF3B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SF3B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PAFAH1B1 Human Pre-designed siRNA Set A contains three designed siRNAs for PAFAH1B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
